HSP (e.g. HSP90)

Signaling Pathway Map

Research Area

Inhibitory Selectivity
Solubility

Catalog No.	Product Name	Solubility(25°C)
Catalog No.	Product Name	Water	DMSO	Alcohol
S1141	Tanespimycin (17-AAG)	<1 mg/mL	100 mg/mL	5 mg/mL
S1069	Luminespib (AUY-922, NVP-AUY922)	<1 mg/mL	93 mg/mL	31 mg/mL
S1142	Alvespimycin (17-DMAG) HCl	<1 mg/mL	131 mg/mL	<1 mg/mL
S1159	Ganetespib (STA-9090)	<1 mg/mL	40 mg/mL	<1 mg/mL
S1175	BIIB021	<1 mg/mL	64 mg/mL	2 mg/mL
S1163	Onalespib (AT13387)	<1 mg/mL	25 mg/mL	<1 mg/mL
S1498	NVP-BEP800	<1 mg/mL	<1 mg/mL	15 mg/mL
S2713	Geldanamycin	<1 mg/mL	36 mg/mL	<1 mg/mL
S2639	SNX-2112 (PF-04928473)	<1 mg/mL	93 mg/mL	1 mg/mL
S2656	PF-04929113 (SNX-5422)	<1 mg/mL	104 mg/mL	5 mg/mL
S2685	KW-2478	<1 mg/mL	115 mg/mL	3 mg/mL
S7122	XL888	<1 mg/mL	100 mg/mL	<1 mg/mL
S7282	NMS-E973	<1 mg/mL	90 mg/mL	<1 mg/mL
S8039	PU-H71	34 mg/mL	100 mg/mL	100 mg/mL
S8365	Apoptozole	<1 mg/mL	100 mg/mL	25 mg/mL
S8402	KRIBB11	<1 mg/mL	3 mg/mL	<1 mg/mL
S7750	KNK437	<1 mg/mL	15 mg/mL	<1 mg/mL
S7458	VER-49009	<1 mg/mL	77 mg/mL	<1 mg/mL
S7340	CH5138303	<1 mg/mL	83 mg/mL	<1 mg/mL
S7459	VER-50589	<1 mg/mL	77 mg/mL	77 mg/mL
S7751	VER155008	<1 mg/mL	100 mg/mL	<1 mg/mL
S1141	Tanespimycin (17-AAG)	<1 mg/mL	100 mg/mL	5 mg/mL
S1069	Luminespib (AUY-922, NVP-AUY922)	<1 mg/mL	93 mg/mL	31 mg/mL
S1142	Alvespimycin (17-DMAG) HCl	<1 mg/mL	131 mg/mL	<1 mg/mL
S1159	Ganetespib (STA-9090)	<1 mg/mL	40 mg/mL	<1 mg/mL
S1175	BIIB021	<1 mg/mL	64 mg/mL	2 mg/mL
S1163	Onalespib (AT13387)	<1 mg/mL	25 mg/mL	<1 mg/mL
S1498	NVP-BEP800	<1 mg/mL	<1 mg/mL	15 mg/mL
S2713	Geldanamycin	<1 mg/mL	36 mg/mL	<1 mg/mL
S2639	SNX-2112 (PF-04928473)	<1 mg/mL	93 mg/mL	1 mg/mL
S2656	PF-04929113 (SNX-5422)	<1 mg/mL	104 mg/mL	5 mg/mL
S2685	KW-2478	<1 mg/mL	115 mg/mL	3 mg/mL
S7122	XL888	<1 mg/mL	100 mg/mL	<1 mg/mL
S7282	NMS-E973	<1 mg/mL	90 mg/mL	<1 mg/mL
S8039	PU-H71	34 mg/mL	100 mg/mL	100 mg/mL
S8365	Apoptozole	<1 mg/mL	100 mg/mL	25 mg/mL
S8402	KRIBB11	<1 mg/mL	3 mg/mL	<1 mg/mL
S7750	KNK437	<1 mg/mL	15 mg/mL	<1 mg/mL
S7458	VER-49009	<1 mg/mL	77 mg/mL	<1 mg/mL
S7340	CH5138303	<1 mg/mL	83 mg/mL	<1 mg/mL
S7459	VER-50589	<1 mg/mL	77 mg/mL	77 mg/mL
S7751	VER155008	<1 mg/mL	100 mg/mL	<1 mg/mL

Isoform-specific Inhibitors

HSP (e.g. HSP90) Inhibitors (42)

Catalog No.	Information	Product Use Citations	Product Validations
S1141	Tanespimycin (17-AAG) Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.	Mol Cell, 2013, 50(3):368-78 J Exp Med, 2012, 209(2):259-73 P Natl Acad Sci USA, 2011, 108(18):7535-40	(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.
S1069	Luminespib (AUY-922, NVP-AUY922) Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.	Nat Med, 2015, 10.1038/nm.3855 Nat Commun, 2014, 5:3361 Proc Natl Acad Sci USA, 2014, 111(15):E1528-37	U2OS_exo cells were incubated with AUY922 for 20 h at the indicated concentrations before stimulation with TNFα (30 ng/mL) for 30 min and immunostaining to detect NF-κB (p65). DMSO 1%, cells stimulated by TNFα in the absence of AUY922. Representative pictures used to quantify nuclear and cytoplasmic localization of NF-κB.
S1142	Alvespimycin (17-DMAG) HCl Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.	Hepatology, 2013, 57(1):70-80 J Thorac Oncol, 2012, 7(7):1078-85 Mol Oncol, 2013, 7(6):1093-102	H2228/Vec or H2228/HGF cells were treated with or without alectinib (0.3 μmol/L) for 2 h or 17-DMAG (0.3 μmol/L) for 24 h and then stimulated with or without HGF (50 ng/mL) for 10 minutes. The resultant cells were lysed, and the indicated proteins were detected by immunoblotting.
S1159	Ganetespib (STA-9090) Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.	Nature, 2017, 10.1038/nature21064 Cell, 2017, 168(5):856-866 Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1017	Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.
S1175	BIIB021 BIIB021 is an orally available, fully synthetic small-molecule inhibitor of HSP90 with K_i and EC50 of 1.7 nM and 38 nM, respectively. Phase 2.	Cell, 2017, 168(5):856-866 Arthritis Rheumatol , 2013, 65(8):2102-12 PLoS Pathog, 2012, 8(11):e1003048
S1163	Onalespib (AT13387) Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.	Cell, 2017, 168(5):856-866 PLoS One, 2013, 8(4):e59315 Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7	Relative effect of pharmacological HSP90 inhibition by (B) onalespib (AT13387, 10-40 nM) on the viability of FANCA wild-type and FANCA null cells under normal conditions or with increasing concentrations of MMC. Left panels indicate the effects of the indicated inhibitor on cell growth; middle panels the effects onMMCtolerance in FANCA-wild-type cells; right panels the effects onMMCtolerance in FANCA null cells Data presented as the mean ± SEM from 2 independent experiments.
S1498	NVP-BEP800 NVP-BEP800 is a novel, fully synthetic HSP90β inhibitor with IC50 of 58 nM, exhibits>70-fold selectivity against Hsp90 family members Grp94 and Trap-1.	Cancer Cell, 2012, 20(3):400-13 Mol Cancer, 2017, 16(1):72 PLoS Pathog, 2012, 8(11):e1003048	Growth curves of the MPNST cell line S462 treated with two different HSP90 inhibitors (500nM IPI-504 and 500nM BEP800).
S2713	Geldanamycin Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.	J Antimicrob Chemother, 2015, 10.1093/jac/dku549 Antimicrob Agents Chemother, 2015, 59(8):4727-33 PLoS One, 2015, 10(9):e0138936	Phenotypic effect of Genetic or Pharmacologic Compromise of the 477 Hsp70-StiA-Hsp90 Complex. The impact of each genetic modification on radial growth, conidiation, and response to various stress conditions was assessed after inoculation of a suspension of 104 conidia on glucose minimal medium (GMM) agar plates and incubation at 37ºC for 5 days.
S2639	SNX-2112 (PF-04928473) SNX-2112 (PF-04928473) selectively binds to the ATP pocket of HSP90α and HSP90β with K_a of 30 nM and 30 nM, uniformly more potent than 17-AAG.	PLoS Negl Trop Dis, 2014, 8(2):e2699 Mol Cell Biol, 2013, 33(12):2375-87 Immunopharmacol Immunotoxicol, 2015, 8:1-10
S2656	PF-04929113 (SNX-5422) PF-04929113 (SNX-5422) is a potent and selective HSP90 inhibitor with K_d of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2.	Antimicrob Agents Chemother, 2014, 58(7):4138-44 J Biol Chem, 2013, 288(23):16308-20 Endocrine, 2016, 51(2):274-82	Effect of SNX-2112 on E. histolytica morphology. Trophozoites were treated with 3 uM SNX-2112 for 48 h. (A) E. histolytica trophozoites treated with 0.5% DMSO. Arrow indicates live trophozoite. Magnification, x 10. (B) E. histolytica trophozoites treated with 3 uM SNX-2112. Treatment caused complete lysis of trophozoites (arrow). Magnification, x 10. Trophozoites were imaged under phase-contrast microscope.
S2685	KW-2478 KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM. Phase 1.
S7122	XL888 XL888 is an ATP-competitive inhibitor of HSP90 with IC50 of 24 nM. Phase 1.	Clin Cancer Res, 2012, 18(9):2502-14	B, XL888 (1 mmol/L, 144 hours) is effective at blocking the growth and survival of vemurafenib-resistant melanoma cell lines grown as 3D collagen-implanted spheroids. Staining shows cell viability, in which green corresponds to live cells and red: dead cells. Magnification×4.
S7282	NMS-E973 NMS-E973 is a potent and selective Hsp90 inhibitor with DC50 of <10 nM for Hsp90 binding, no activiy against a panel of 52 diverse protein kinases.		(D) Representative images of paraffin-embedded tumor sections were analyzed by active caspase-3 staining. (E) Representative images of paraffin-embedded tumor sections analyzed by TUNEL staining.
S8039	PU-H71 PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.	Cell, 2017, 168(5):856-866 Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7	Effects of low-level HSP90 inhibition (by ganetespib, 2-5 nM; PU-H71, 40-70 nM) or febrile-range temperature (39 ℃) on HSP70 and HSP90 protein levels in FANCA wild-type cells. High-level HSP90 inhibition (ganetespib, 25 nM; PU-H71, 300 nM) as well as proteotoxic proteasomal inhibition (MG132, 2.5 mM) induced the expression of HSP70. Constitutive (upper band: C) and inducible forms (lower band: I) of HSP70 are indicated. HSP90 levels are shown for comparison.
S8365	Apoptozole Apoptozole is an inhibitor of heat shock protein 70(HSP70) and Hsc70 with dissociation constants Kd of 0.14 μM and 0.21 μM, respectively. It induces caspase-dependent apoptosis.		Representative images of platelets preincubated with FITC-conjugated CD41 before treated with negative control, pitstop 2, dynasore, A23, or apoptozole spreading on immobilized Fg for 10, 30, and 60 minutes, respectively. Images were taken under oil immersion with magnification × 100. Scale bar, 5 μm.
S8402	KRIBB11 KRIBB11 abolishes the heat shock-induced luciferase activity with an IC50 of 1.2 μM. It is an inhibitor of the transcription factor Heat Shock Factor 1 (HSF1).
S7750	KNK437 KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.	Br J Haematol, 2013, 161(5):667-76 Oncol Rep, 2012, 28(6):1953-8	Western blots of lysates from BaF3 JAK2 V617F cells.
S7458	VER-49009 VER-49009 is a potent HSP90 inhibitor with IC50 of 47 nM for HSP90β.
S7340	CH5138303 CH5138303 is an orally available Hsp90 inhibitor with K_d of 0.48 nM.
S7459	VER-50589 VER-50589 is a potent HSP90 inhibitor with IC50 of 21 nM for HSP90β.	PLoS Negl Trop Dis, 2014, 8(2):e2699
S7751	VER155008 VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.	Cell Signal, 2017, 30:130-141 Neuroscience, 2014, 281C:164-177	C, HSP70 protein levels after 1000 ng/mL LPS treatment combined with or without HSP70 inhibitor VER155008 for 48 h using western blot analysis, respectively. D, HSP70 protein levels after heat stress treatment combined with or without HSP70 inhibitor VER155008 for 3 h using western blot analysis.
S1141	Tanespimycin (17-AAG) Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.	Mol Cell, 2013, 50(3):368-78 J Exp Med, 2012, 209(2):259-73 P Natl Acad Sci USA, 2011, 108(18):7535-40	(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.
S1069	Luminespib (AUY-922, NVP-AUY922) Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.	Nat Med, 2015, 10.1038/nm.3855 Nat Commun, 2014, 5:3361 Proc Natl Acad Sci USA, 2014, 111(15):E1528-37	U2OS_exo cells were incubated with AUY922 for 20 h at the indicated concentrations before stimulation with TNFα (30 ng/mL) for 30 min and immunostaining to detect NF-κB (p65). DMSO 1%, cells stimulated by TNFα in the absence of AUY922. Representative pictures used to quantify nuclear and cytoplasmic localization of NF-κB.
S1142	Alvespimycin (17-DMAG) HCl Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.	Hepatology, 2013, 57(1):70-80 J Thorac Oncol, 2012, 7(7):1078-85 Mol Oncol, 2013, 7(6):1093-102	H2228/Vec or H2228/HGF cells were treated with or without alectinib (0.3 μmol/L) for 2 h or 17-DMAG (0.3 μmol/L) for 24 h and then stimulated with or without HGF (50 ng/mL) for 10 minutes. The resultant cells were lysed, and the indicated proteins were detected by immunoblotting.
S1159	Ganetespib (STA-9090) Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.	Nature, 2017, 10.1038/nature21064 Cell, 2017, 168(5):856-866 Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1017	Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.
S1175	BIIB021 BIIB021 is an orally available, fully synthetic small-molecule inhibitor of HSP90 with K_i and EC50 of 1.7 nM and 38 nM, respectively. Phase 2.	Cell, 2017, 168(5):856-866 Arthritis Rheumatol , 2013, 65(8):2102-12 PLoS Pathog, 2012, 8(11):e1003048
S1163	Onalespib (AT13387) Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.	Cell, 2017, 168(5):856-866 PLoS One, 2013, 8(4):e59315 Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7	Relative effect of pharmacological HSP90 inhibition by (B) onalespib (AT13387, 10-40 nM) on the viability of FANCA wild-type and FANCA null cells under normal conditions or with increasing concentrations of MMC. Left panels indicate the effects of the indicated inhibitor on cell growth; middle panels the effects onMMCtolerance in FANCA-wild-type cells; right panels the effects onMMCtolerance in FANCA null cells Data presented as the mean ± SEM from 2 independent experiments.
S1498	NVP-BEP800 NVP-BEP800 is a novel, fully synthetic HSP90β inhibitor with IC50 of 58 nM, exhibits>70-fold selectivity against Hsp90 family members Grp94 and Trap-1.	Cancer Cell, 2012, 20(3):400-13 Mol Cancer, 2017, 16(1):72 PLoS Pathog, 2012, 8(11):e1003048	Growth curves of the MPNST cell line S462 treated with two different HSP90 inhibitors (500nM IPI-504 and 500nM BEP800).
S2713	Geldanamycin Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.	J Antimicrob Chemother, 2015, 10.1093/jac/dku549 Antimicrob Agents Chemother, 2015, 59(8):4727-33 PLoS One, 2015, 10(9):e0138936	Phenotypic effect of Genetic or Pharmacologic Compromise of the 477 Hsp70-StiA-Hsp90 Complex. The impact of each genetic modification on radial growth, conidiation, and response to various stress conditions was assessed after inoculation of a suspension of 104 conidia on glucose minimal medium (GMM) agar plates and incubation at 37ºC for 5 days.
S2639	SNX-2112 (PF-04928473) SNX-2112 (PF-04928473) selectively binds to the ATP pocket of HSP90α and HSP90β with K_a of 30 nM and 30 nM, uniformly more potent than 17-AAG.	PLoS Negl Trop Dis, 2014, 8(2):e2699 Mol Cell Biol, 2013, 33(12):2375-87 Immunopharmacol Immunotoxicol, 2015, 8:1-10
S2656	PF-04929113 (SNX-5422) PF-04929113 (SNX-5422) is a potent and selective HSP90 inhibitor with K_d of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2.	Antimicrob Agents Chemother, 2014, 58(7):4138-44 J Biol Chem, 2013, 288(23):16308-20 Endocrine, 2016, 51(2):274-82	Effect of SNX-2112 on E. histolytica morphology. Trophozoites were treated with 3 uM SNX-2112 for 48 h. (A) E. histolytica trophozoites treated with 0.5% DMSO. Arrow indicates live trophozoite. Magnification, x 10. (B) E. histolytica trophozoites treated with 3 uM SNX-2112. Treatment caused complete lysis of trophozoites (arrow). Magnification, x 10. Trophozoites were imaged under phase-contrast microscope.
S2685	KW-2478 KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM. Phase 1.
S7122	XL888 XL888 is an ATP-competitive inhibitor of HSP90 with IC50 of 24 nM. Phase 1.	Clin Cancer Res, 2012, 18(9):2502-14	B, XL888 (1 mmol/L, 144 hours) is effective at blocking the growth and survival of vemurafenib-resistant melanoma cell lines grown as 3D collagen-implanted spheroids. Staining shows cell viability, in which green corresponds to live cells and red: dead cells. Magnification×4.
S7282	NMS-E973 NMS-E973 is a potent and selective Hsp90 inhibitor with DC50 of <10 nM for Hsp90 binding, no activiy against a panel of 52 diverse protein kinases.		(D) Representative images of paraffin-embedded tumor sections were analyzed by active caspase-3 staining. (E) Representative images of paraffin-embedded tumor sections analyzed by TUNEL staining.
S8039	PU-H71 PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.	Cell, 2017, 168(5):856-866 Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7	Effects of low-level HSP90 inhibition (by ganetespib, 2-5 nM; PU-H71, 40-70 nM) or febrile-range temperature (39 ℃) on HSP70 and HSP90 protein levels in FANCA wild-type cells. High-level HSP90 inhibition (ganetespib, 25 nM; PU-H71, 300 nM) as well as proteotoxic proteasomal inhibition (MG132, 2.5 mM) induced the expression of HSP70. Constitutive (upper band: C) and inducible forms (lower band: I) of HSP70 are indicated. HSP90 levels are shown for comparison.
S8365	Apoptozole Apoptozole is an inhibitor of heat shock protein 70(HSP70) and Hsc70 with dissociation constants Kd of 0.14 μM and 0.21 μM, respectively. It induces caspase-dependent apoptosis.		Representative images of platelets preincubated with FITC-conjugated CD41 before treated with negative control, pitstop 2, dynasore, A23, or apoptozole spreading on immobilized Fg for 10, 30, and 60 minutes, respectively. Images were taken under oil immersion with magnification × 100. Scale bar, 5 μm.
S8402	KRIBB11 KRIBB11 abolishes the heat shock-induced luciferase activity with an IC50 of 1.2 μM. It is an inhibitor of the transcription factor Heat Shock Factor 1 (HSF1).
S7750	KNK437 KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.	Br J Haematol, 2013, 161(5):667-76 Oncol Rep, 2012, 28(6):1953-8	Western blots of lysates from BaF3 JAK2 V617F cells.
S7458	VER-49009 VER-49009 is a potent HSP90 inhibitor with IC50 of 47 nM for HSP90β.
S7340	CH5138303 CH5138303 is an orally available Hsp90 inhibitor with K_d of 0.48 nM.
S7459	VER-50589 VER-50589 is a potent HSP90 inhibitor with IC50 of 21 nM for HSP90β.	PLoS Negl Trop Dis, 2014, 8(2):e2699
S7751	VER155008 VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.	Cell Signal, 2017, 30:130-141 Neuroscience, 2014, 281C:164-177	C, HSP70 protein levels after 1000 ng/mL LPS treatment combined with or without HSP70 inhibitor VER155008 for 48 h using western blot analysis, respectively. D, HSP70 protein levels after heat stress treatment combined with or without HSP70 inhibitor VER155008 for 3 h using western blot analysis.

Choose Your Country or Region

By Signaling Pathways

By product type

HSP (e.g. HSP90)

Signaling Pathway Map

Research Area

Isoform-specific Inhibitors